{"article": [{"url": "https://www.marketwatch.com/story/modernas-stock-surges-as-new-funding-sets-phase-3-trial-of-covid-19-vaccine-candidate-to-start-immediately-2020-07-27", "published": 1595831840.0, "headline": "Moderna's stock surges as new funding sets Phase 3 trial of COVID-19 vaccine candidate to start 'immediately'", "body": "Shares of Moderna Inc. MRNA, +0.09% rallied 7.0% in premarket trading Monday, after the biopharmaceutical company announced over the weekend another $472 million commitment from the government to develop a COVID-19 vaccine. SVB Leerink analyst Mani Foroohar said that commitment, which is in addition to the previous commitment of $483 million, will be used to fun the Phase 3 trial of its vaccine candidate, which is \"set to begin immediately.\" He reiterated his market perform rating and $65 stock price target, which is 11% below Friday's closing price of $73.21, but said he believes the news will help \"drive near-term recovery\" from the recent weakness. At Friday's close, the stock had dropped 23% from its July 17 record close of $94.85. The stock had still run up nearly fourfold (up 274%) year to date, while the S&P 500 SPX, +0.87% has slipped 0.5%."}]}